HIV-1 infected study participants were predominantly female (67%) and married (76%) with a median age of 33 years (IQR 27 39).
ALAT levels of infected study participants were in the normal range (17 55 IU).
The infected study population in this study was predominately male (67.69%) and averaged above 40 years of age, which is similar to recent studies [ 3, 20].
Thus, PTLC was calculated as the number of newly diagnosed HIV-infected study participants who did not return for a CD4 test within 8 weeks of HIV diagnosis divided by the total number of newly diagnosed HIV-infected study participants.
All KSHV-infected and non-infected study participants were recruited from Chelsea and Westminster Hospital, London, UK, and provided written, informed consent.
HIV-infected study participants with one, two and three of these risk factors for PTLC were 1.88, 2.50 and 3.84 times more likely to have PTLC compared to study participants with no risk factors (p-value for linear trend <0.0001).
Health expenditures were stratified into two groups: expenditures related to treatment of the HIV-infected study subject, and expenditures related to the treatment of other members of the family (whose HIV serostatus was unknown).
The present study was performed to identify immunological variables in two E. histolytica-infected study populations from the same endemic region of Vietnam.
CD4 cell counts were measured every 6 months among HIV-infected study participants not yet on ART, using FACS Count Machine (Becton Dickinson, San Jose, California, USA).
In addition, our HIV-infected study population was hospitalized and severely immunosuppressed, with more than 75% patients having a CD4+ T-lymphocyte count < 200 cells/μl.
